A Cost-effectiveness Analysis of Adjuvant Alectinib in Patients With Resectable ALK-positive Non-small Cell Lung Cancer in the United States

By afschroeder • October 10, 2025

Cummings AL, Sussell J, Rosettie KL, El Moustaid F, Ogale S, Ngiam C, Jovanoski N, Arnold M, Lee JM. A Cost-effectiveness Analysis of Adjuvant Alectinib in Patients With Resectable ALK-positive Non-small Cell Lung Cancer in the United States. Am J Clin Oncol. 2025 Oct 8. doi: 10.1097/COC.0000000000001248. Epub ahead of print. PMID: 41066159.

Tags: adjuvant treatment, Alectinib, anaplastic lymphoma kinase, Hematology/Oncology, Non-small cell lung cancer, platinum-based chemotherapy, Publications, Pulmonary, Critical Care & Sleep Medicine

Real-world clinical outcomes of Trastuzumab Deruxtecan in HER2-expressing ovarian and endometrial Cancer

Silverstein J, Alomaja O, Chatram D, Hajiabbasi M, Shachar E, Tseng CH, Thaker S, Bardia A, Karlan B, Hendrickson AW, Konecny GE. Real-world clinical outcomes[...]

Fixed-duration epcoritamab plus R-CHOP in newly diagnosed LBCL with IPI score 3-5: results from the EPCORE NHL-2 trial

Falchi L, Offner F, de Vos S, Brody JD, Morillo D, Linton K, Snauwaert S, Roost Clausen M, Karimi YH, Thieblemont C, Vitolo U, Leslie[...]

Danvatirsen plus pembrolizumab versus pembrolizumab for recurrent and/or metastatic head and neck squamous cell carcinoma (PEMDA-HN): a randomized, phase 2 trial

Saba NF, Posner M, Harrington K, Neupane P, Rezaee R, Nenclares P, Jimeno A, Denker AE, MacIntyre S, Makris L, Wong D. Danvatirsen plus pembrolizumab[...]